Excellergy Therapeutics

Excellergy | The First Trifunctional Effector Cell Response Inhibitors (ECRIs)

Excellergy Therapeutics is headquartered in United States and has $70.0M in recorded funding across 1 round.

Business Model
B2B
Total Funding
$70.0M
Last Round
$70.0M Series AOct 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 3 investors for this company. The full record is or through the API.

About

Excellergy is a biotech company developing Exl-111, the first Trifunctional Effector Cell Response Inhibitor (ECRI), a next-generation anti-IgE therapeutic designed to combine IgE neutralization, receptor-bound IgE removal, and FcεRI downregulation to rapidly desensitize allergic patients. Co-founded by immunologist Dr. Alexander Eggel, the underlying science was validated through Nature-published research and a collaboration with Stanford University.

Summary

Excellergy Therapeutics is a Biotech company based in United States. It has raised $70.0M in total across 1 round, most recently a $70.0M Series A round in Oct 2025. Investors include Samsara BioCapital, Red Tree Venture Capital and Decheng Capital.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AOct 2025
$70.0M

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
ParexelAcquired

One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...

Raleigh, United States10001+Biotech
Private EquityTotal funding$5.0BJun 2017
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Excellergy Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/excellergy-therapeutics"><img src="https://indexed.vc/api/badge/company/excellergy-therapeutics" alt="Excellergy Therapeutics on Indexed.vc" width="260" height="76" /></a>